Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents Final Appraisal Recommendation Advice No: 1319 – October 2019 Glecaprevir/pibrentasvir (Maviret ® ) 100 mg/40 mg film-coated tablets Limited submission by AbbVie Ltd. Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (...) as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to < 18 years. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Final

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin, improving subcutaneous insulin's hepatic biodistribution. We assessed HDV-insulin lispro (HDV-L) versus insulin lispro (LIS) in type 1 diabetes (T1D).Insulin Liver Effect (ISLE-1) was a 26-week, phase 2b, multicenter, randomized, double-blind, noninferiority trial.Among 176

Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy '); } else { document.write(' '); } ACE | Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Search > > Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy - Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Rifaximin 550 mg tablet as add (...) -on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy. Subsidy status Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C Search > > Direct-acting antiviral agent for treating genotype 2 to 6 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C First published on 2 January 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration: 12 weeks' treatment of sofosbuvir/velpatasvir for patients with genotype 2 to 6 hepatitis C virus without cirrhosis or with compensated cirrhosis (Child

Options for national testing and surveillance for hepatitis E virus in the EU/EEA TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance www.ecdc.europa.euECDC TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Cornelia Adlhoch and produced by Cornelia (...) on request. Representatives of the European Food Safety Authority (EFSA, Valentina Rizzi and Michaela Hempen) and the World Health Organization Regional Office for Europe (Antons Mozalevskis) were observers in this group and received documents for review. The work was supported by two service contracts No. ECD.7600 (HEV epidemiological support – P/2017/OCS/253) and No. ID 5132 (Hepatitis B, C, and E in the EU/EEA: monitoring and testing activities). The following staff were involved on the contractor’s

Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B vaccine (HepB) on day 1 and EV71 vaccine (dose 2) with group A meningococcal (...) ); or administration of HepB and MenA on days 1 and 30, respectively (the SE2 group).According to the per protocol set, antibody responses against EV71, hepatitis B virus (HBV), and group A meningococcal polysaccharide were similar regardless of administration schedule. With the non-inferiority margin setting at 10%, the seroconversion rates of the three pathogens in the SI group (100% [98.25, 100], 44.84% [38.20, 51.63] and 27.83% [21.91, 34.38]) were not inferior to those in SE1 or SE2 group (100% [98.31, 100

The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake (...) of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3 × 2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1747 participants, 47.7% (n = 833) received 0 doses of HBV vaccine, 27.8% (n = 485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation (p = .59). Mean

Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Joseph Doyle, Michelle Raggatt, Monica Slavin, Sue‐Anne McLachlan, Simone I Strasser, Joseph J Sasadeusz, Jessica Howell, Krispin Hajkowicz, Harshal Nandurkar, Anna Johnston, Narin Bak and Alexander J Thompson Med J

Hepatitis C: interventions for case-finding and linkage to care Hepatitis C: interventions for case-finding and linkage to care - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis C: interventions for case-finding and linkage to care An evidence review of what interventions are effective in increasing case-finding and linkage to care for hepatitis C-infected patients. Published 26 July 2019 From (...) need. It will help us if you say what assistive technology you use. Details This report summarises the evidence for interventions, to increase case-finding and linkage to care for hepatitis C-infected patients. It is intended to support commissioners and health and care providers, in making decisions on prioritisation of resources and the commissioning of services. It is part of the ongoing effort to eliminate hepatitis C virus ( Collection Explore the topic Is this page useful? Thank you for your

Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) , -7.6 to -4.2 percentage points]; aHR, 0.41 [CI, 0.32 to 0.61]), and 10-year mortality was significantly lower among both lipophilic (15.2% vs. 7.3%; RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points]) and hydrophilic (16.0% vs. 11.5%; RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points]) statin users.Lack of lipid, fibrosis, or HCC surveillance data.In a nationwide viral hepatitis cohort, lipophilic statins were associated with significantly reduced HCC incidence

Acupuncture for chronic hepatitis B. Chronic hepatitis B is a liver disease associated with high morbidity and mortality. Chronic hepatitis B requires long-term management aiming to reduce the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, as well as to improve health-related quality of life. Acupuncture is being used to decrease discomfort and improve immune function in people with chronic hepatitis B. However (...) , the benefits and harms of acupuncture still need to be established in a rigorous way.To assess the benefits and harms of acupuncture versus no intervention or sham acupuncture in people with chronic hepatitis B.We undertook electronic searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index Expanded, Conference Proceedings Citation Index - Science, China National Knowledge Infrastructure (CNKI), Chongqing VIP (CQVIP), Wanfang Data

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism (...) in patients with liver disease is thought to be driven by decreased osteoblast activity. Patients with liver disease see decreases in osteoblastogenesis stimulating factors such as IGF-1 and vitamin K and increases in serum bilirubin, which directly inhibits osteoblastogenesis. It is recommended to screen the following female and male patients for hepatic osteopenia: All patients with cirrhosis All patients with chronic cholestasis (bilirubin >3mg/dL for 6 months) All potential liver transplant candidates

Daratumumab (Darzalex): risk of reactivation of hepatitis B virus Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab (...) . Published 19 August 2019 From: Therapeutic area: , , , , Contents Advice for healthcare professionals: hepatitis B virus reactivation has been reported in patients treated with daratumumab, including several fatal cases worldwide screen all patients for hepatitis B virus before initiation of daratumumab; patients with unknown serology who are already on treatment should also be screened monitor patients with positive serology for clinical and laboratory signs of hepatitis B reactivation during treatment

Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement. Screening for hepatitis B virus (HBV) infection during pregnancy identifies women whose infants are at risk of perinatal transmission. Data from a nationally representative sample showed a prevalence of maternal HBV infection of 85.8 cases per 100 000 deliveries from 1998 to 2011 (0.09% of live-born singleton deliveries in the United States). Although (...) commissioned a reaffirmation evidence update to identify substantial new evidence sufficient enough to change the prior recommendation. The USPSTF targeted its evidence review on the effectiveness and potential harms of screening and the effectiveness and harms of case management to prevent perinatal transmission.The USPSTF previously found adequate evidence that serologic testing for hepatitis B surface antigen accurately identifies HBV infection. Interventions are effective for preventing perinatal

An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut A 12-week grazoprevir/elbasvir regimen is highly effective against hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of an 8-week regimen for treatment-naive HCV-1-infected patients with mild fibrosis has not been

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, treatment and prevention - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, treatment and prevention Updated 8 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view (...) this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-prevention-treatment/hepatitis-e-symptoms-transmission-treatment-and-prevention Background Hepatitis E is an illness of the liver caused

Hepatitis B vaccine for renal patients: patient group direction template application/vnd.openxmlformats-officedocument.wordprocessingml.document

Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study Frailty is associated with mortality in patients with cirrhosis. We measured frailty using 3 simple tests and calculated Liver Frailty Index (LFI) scores for patients at multiple ambulatory centers. We investigated associations between LFI scores, ascites, and hepatic encephalopathy (HE) and mortality.Adults without hepatocellular carcinoma who were on the liver transplantation